Otsuka’s Q1 Pharma Sales Up 11.9% Driven by Global Brands, Profits Dip on FDA Vadadustat Snub

Otsuka Holdings saw its first quarter pharmaceutical revenue rise 11.9% buoyed by growth of its four global brands. However, profit for the same segment contracted 8.7% on the back of increased R&D spending and an impairment loss incurred related to...read more